4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT, will participate in a fireside chat at the Evercore ISI HealthCONx 2022 Conference. The fireside chat will take place on Wednesday, November 30, 2022 at 3:55 p.m. ET. A live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available following the live event. About 4DMT4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximat
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.MarketBeat
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.MarketBeat
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.MarketBeat
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.MarketBeat
FDMT
Earnings
- 11/9/23 - Beat
FDMT
Sec Filings
- 4/18/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- FDMT's page on the SEC website